Molecular and serological investigation of the 2021 COVID-19 case surge in Mongolian vaccinees

Introduction

In March 2021 an increase in COVID-19 cases in Mongolia (population 3.3 million) led to a government-mandated shutdown and a nationwide vaccination program with four different vaccines. In early June, a reduction in cases attributed to vaccination led to relaxation of the shutdown that was followed by a surge in disease (Figure. 1).

• Download figure
• Open in new tab

Figure 1.

A] Time line of COVID-19 in Mongolia February 2020 - July 2021; B] Illustration of daily new cases in Mongolia with 3 days and seven days moving average of daily new cases (blue plot lines) Source: https://www.worldometers.info/coronavirus/country/mongolia/

To determine whether the surge was due to the emergence of Delta or another variant, or vaccine failure, a rapid, opportunistic investigation was conducted that comprised virus sequence analysis of nasal swab samples from breakthrough cases and antibody assays of plasma from healthy vaccinees.

Methods

Samples were collected with informed consent. RNA from nasal swabs was extracted for Illumina sequencing using the Mybaits capture system (Arbor Biosciences). Reads were mapped and aligned to SARS-CoV-2 reference sequence (accession no. NC_045512) and variant analyses performed using GISAID, NextClade[1]. Plasma from healthy vaccinees were screened for anti-SARS-CoV-2 antibodies in EUROIMMUN Anti-SARS-CoV-2 IgG ELISA and EUROIMMUN Anti-SARS-CoV-2 NCP IgG ELISA. Neutralizing antibodies (NAb) to Washington, and Delta SARS-CoV-2 variants were quantitated in an absolute end point neutralization assay that measures 100% neutralizing activity with a SARS-CoV-2 qPCR [2].

Results

We sequenced 97 nasal samples from Covid-19 patients with breakthrough infections after vaccination (Supplementary Table 1), and tested plasma from 100 healthy subjects for antibodies to SARS-CoV-2 (surface glycoprotein, S and nucleocapsid phosphoprotein, NCP), and NAb after Covishield/AstraZeneca, Sputnik V, Sinopharm, or Pfizer/BioNTech vaccination (Table 1).

Full-length SARS-CoV-2 sequences were obtained from 92 samples. Eighty-seven of 92 (94.6%) were Alpha variant. Five of 92 (5.4%) were Delta variant. Of 87 Alpha variant breakthrough infections, 54 (62.1 %) were from Sinopharm, 7 (8.0%) from Sputnik V, 23 (26.4%) from Covishield/AZN, and 3 (3.4%) from Pfizer/BioNTech vaccinees. Of 5 breakthrough Delta variant infections, 1 (20%) was from Sinopharm, 3 (60%) were from Covishield/AZN, and 1 (20%) was from Pfizer/BioNTech vaccinees (Supplementary Table 1).

More subjects had spike ELISA reactivity after Pfizer/BioNTech (91.6%), and Covishield/AstraZeneca (70.8%), than Sputnik V (29.2%) or Sinopharm (12.5%). Nucleoprotein reactivity was present in 12.5% of Sinopharm vaccinees. One Covishield/AstraZeneca vaccinee was NP positive, presumably because of infection. Only Sinopharm contains NP. Three of four subjects (75%) who received two Sinopharm doses followed by one Pfizer/BioNTech dose were spike-positive (Table 1) (Supplemental Figure 1). More subjects had NAb to WA strain after Pfizer/BioNTech (79.7%), and Covishield/AstraZeneca (50.0%), than after Sputnik V (25.0%) or Sinopharm (20.8%). Neutralizing antibodies to Delta variants were present in fewer subjects after Pfizer/BioNTech (29.2%), Sputnik V (8.33%), and Sinopharm (12.5%). NAb to Delta variants were detected in nine subjects after Covishield/AZN (37.50%); however, 3/9 were NCP ELISA-positive indicating previous SARS-CoV-2 exposure. Eliminating these three subjects would decrease the percentage with NAb to Delta to 25%. Three of four vaccinees who received a single dose of Pfizer/BioNTech after two doses of Sinopharm had NAb to WA; one had NAb to Delta.

Discussion

Our findings provide additional support for ordinal hierarchy of protection amongst vaccine platforms, with mRNA vaccines performing better than adenovirus-vectored or killed virus vaccines [3]. They also confirm that current vaccines, based on the prototypic WA strain, elicit only minimal levels of NAb to current circulating strains [4 ,5]. The case surge in Mongolia in June 2021 did not reflect the introduction of the Delta variant but premature relaxation of physical distancing and masking. These findings underscore the importance of continuous surveillance for virus evolution, coordinated modification of vaccines, and a cautious approach to the elimination of classical social controls for mitigating contagion.

Limitations

Our study was limited in numbers and in its retrospective collection of specimens.

Article Information